Head-To-Head Review: Zoetis (ZTS) and Aratana Therapeutics (PETX)

Zoetis (NYSE: ZTS) and Aratana Therapeutics (NASDAQ:PETX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations for Zoetis and Aratana Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zoetis 1 4 12 0 2.65
Aratana Therapeutics 0 0 4 0 3.00

Zoetis currently has a consensus price target of $64.41, suggesting a potential upside of 7.84%. Aratana Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 74.22%. Given Aratana Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Aratana Therapeutics is more favorable than Zoetis.


This table compares Zoetis and Aratana Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Zoetis 17.50% 62.49% 13.14%
Aratana Therapeutics -642.93% -51.21% -32.34%


Zoetis pays an annual dividend of $0.42 per share and has a dividend yield of 0.7%. Aratana Therapeutics does not pay a dividend. Zoetis pays out 23.7% of its earnings in the form of a dividend. Aratana Therapeutics has increased its dividend for 3 consecutive years.

Insider & Institutional Ownership

94.5% of Zoetis shares are owned by institutional investors. Comparatively, 67.9% of Aratana Therapeutics shares are owned by institutional investors. 0.3% of Zoetis shares are owned by company insiders. Comparatively, 5.2% of Aratana Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Zoetis has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Aratana Therapeutics has a beta of 3.4, suggesting that its share price is 240% more volatile than the S&P 500.

Earnings and Valuation

This table compares Zoetis and Aratana Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Zoetis $5.02 billion 5.82 $1.73 billion $1.77 33.75
Aratana Therapeutics $9.28 million 26.60 -$50.68 million ($1.62) -3.54

Zoetis has higher revenue and earnings than Aratana Therapeutics. Aratana Therapeutics is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.


Zoetis beats Aratana Therapeutics on 9 of the 16 factors compared between the two stocks.

About Zoetis

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company’s segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.

About Aratana Therapeutics

Aratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. Its lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). AT-001 is a selective antagonist of the prostaglandin E2 (PGE 2) EP4 receptor (EP4 prostaglandin receptor antagonist or EP4 PRA). AT-002 is a potent and selective ghrelin agonist. Its product candidates also include AT-014, AT-016 and AT-018 for dogs.

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply